The Society of Toxicology 55th Annual Meeting and ToxExpo is next week! ReachBio will be exhibiting at the ToxExpo from March 14th through the 16th. We welcome all to stop by our booth #1300 to talk one-on-one with our scientists, CSO, Dr. Emer Clarke, and Director of Laboratory Operations, Gary dos Santos.
On Tuesday, March 15 Dr. Clarke and Mr. dos Santos will be presenting their latest abstract poster, “An Ex Vivo Platform to Evaluate Compound Effects on Erythroid and Megakaryocyte Development”. Gary dos Santos will be presenting from 9:30AM-12:45PM at Abstract #1833, Poster #139 and looks forward to and questions or discussions you may have on the topic.
This is a wonderful opportunity to discover why our scientific team are the experts in primary cell biology, and how we can use our expertise to help you with your toxicology-related program queries.
Laissez les bon temps rouler! We look forward to seeing you in NOLA!
Date: March 14-16, 2016
Location: New Orleans Ernest N. Morial Convention Center
“An Ex Vivo Platform to Evaluate Compound Effects on Erythroid and Megakaryocyte Development”
Date: March 15, 2016
Abstract: #1833, Poster: #139
Thrombocytopenia and anemia are on-going problems in drug development. Small animal in vivo models, which are commonly used to assess thrombocytopenia and anemia risk at the development stage, often do not translate well into clinical trials. Although progenitor assays, measuring the primitive cells in the bone marrow are excellent at assessing toxicity with some drug classes, it appears that some of these primitive cell populations may be “spared” by the drugs, whereas their progeny – the more mature cells in the blood system- are more susceptible to the toxic effects. We have previously shared data on a megakaryocyte platform that assesses the proliferation and differentiation of cells from early progenitors to mature platelets based on CD41 expression (SOT 2015). This study extends our findings to the erythroid lineage, looking at red blood cell development from primitive CD34+ cells to mature red blood cells. Additionally, we evaluated a method to expand progenitor cells using an aryl hydrolase antagonist, which could provide suitable cell numbers for drug screening using these platforms, and assessed whether the phenotypic profiles of the expanded cells over the course of the study were similar to their non-expanded counterparts.